^
Association details:
| Biomarker: | ALK mutation |
|---|---|
| Cancer: | Melanoma |
| Drug: | Rozlytrek (entrectinib) (ALK inhibitor, TrkB receptor inhibitor, TrkC kinase inhibitor, TrkA receptor inhibitor, ROS1 inhibitor, JAK2 inhibitor, TNK2 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
ALK Inhibitor Response in Melanomas Expressing EML4-ALK Fusions and Alternate ALK Isoforms
Excerpt:
The melanoma PDX tumor MB 3443, which was identified as an ALKATI-expressing melanoma in our screen, was developed from a metastatic tumor of a 62-year-old female diagnosed with mucosal melanoma….A patient with melanoma expressing ALKATI does not respond to treatment with entrectinib.
DOI:
10.1158/1535-7163.MCT-17-0472
